乳腺癌外周血角蛋白-19的检测及其临床意义  

Molecular Detection and Prognostic Value of Cytokeratin-19 in the Peripheral Blood in Patients with Breast Cancer

作　　者：周坚[1] 倪泉兴[1] 邹强[1] 任长才[1] 王红鹰[1] 顾斐[1] 

机构地区：[1]复旦大学附属华山医院普外科,上海200040

出　　处：《中国临床医学》2008年第5期721-724,共4页Chinese Journal of Clinical Medicine

摘　　要：目的:研究反转录酶链聚合反应(RT-PCR)检测乳腺癌患者外周血角蛋白-19(Keratin-19,CK-19)的临床意义。方法:2002年9月—2003年10月,共入选53例乳腺癌患者。分别在术前、术后、第1次化疗结束后以及术后9～12个月,应用反转录酶链聚合反应(RT-PCR)检测血中的CK-19。结果:53例乳腺癌患者中,Ⅰ期、Ⅱ期和Ⅲ期患者CK-19阳性率分别为8.7%,31.82%,71.43%。手术后复查,Ⅱ期患者增加1例。经第1次化疗后,各期原CK-19阳性患者分别减少为2例、3例和2例。结论:运用反转录酶链聚合反应(RT-PCR)检测外周血CK-19敏感性高、特异性好,能成为乳腺癌的一个很好的预后指标,同时亦可用于对化疗的评估。Objective：To explore the feasibility of using the reverse transcriptase-polymerase chain reaction （RT-PCR） technique to detect the cytokeratin 19（CK19） in peripheral blood of breast cancer patients, and to evaluate the effectiveness of the chemotherapy by detect the micrometastasis in peripheral blood. Methods： The levels of CK-19 were evaluated by using RT-PCR at the time of preoperative, postoperative, after the first treatment with chemotherapy and 9-12 months after operation in 53 cases with breast cancer from September 2002 to October 2003. Results： According to World Health Organization tumor staging methods, there was 1 patients in staging 0, 23 patients in staging one, 22 patients in staging two and 7 patients in staging three. Every staging the number of Ck-19（ ＋ ） patients was 0, 2, 7, 5. And postoperative only increased 1 person （at staging two）. After the first treatment with chemotherapy, the number of Ck-19（＋ ） patients decreased to 0, 2, 3, 2. and 9-12 months after operation, the number of Ck-19（ ＋ ） patients decreased to 0, 2, 1, 2. Conclusion：It is a high sensibility and specificity method using RT-PCR to detect CK-19 in peripheral blood of breast cancer patients; It will be a good marker which can find the subclinical metastasis in breast cancer; And It may help the chemotherapy for the patients.

关 键 词：角蛋白-19 反转录酶链聚合反应 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]